Research and original publication material
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Received a Patent for CRYSTALLINE FORM OF 1-CHLORO-4-(BETA-D-GLUCOPYRANOS-1-YL)-2(4-(S)-TETRAHYDROFURAN-3-YLOXY)BENZYL) BENZENE — research background
Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.
Boehringer Ingelheim GmbH operates as a pharmaceutical company. The Company researches, develops, and manufactures pharmaceutical products, as well as offers prescription medicines and consumer health care products for human and animal health. Boehringer Ingelheim serves clients worldwide.
In India, the Pharmaceutical business of Boehringer Ingelheim GmbH is focused on Inhaler, Pharmaceutical blister, Dry powder inhaler, Container for a medicinal liquid, Container for a medicinal liquid, Annelated dihydropyridines and the use thereof for preparing pharmaceutical preparations.
Boehringer Ingelheim International GmBH filed patent application numbered 2756/DELNP/2012 that is titled as METHOD FOR THE PREPARATION OF A CRYSTALLINE FORM OF 1-CHLORO-4-(BETA-D-GLUCOPYRANOS-1-YL)-2(4-(S)-TETRAHYDROFURAN-3-YLOXY)BENZYL) BENZENE. This Patent Application has been granted as Patent Number 318058.
The invention covers Chemical compound. The invention relates to a method for the preparation of a crystalline form of 1-chloro-4- (Β-D-glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) -benzyl ]-benzene. The invention relates to a crystalline form obtainable by this method, to a pharmaceutical composition and to the use thereof for the preparation of medicaments.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act Section 3(d) of the Patents Act, 1970 claimed that the crystalline form of a compound 1-chloro-4-(B-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)- benzyl]-benzene as claimed in claims 6-10 is not patentable u/s 3(d) of the Patents Act, 1970.
As a response, the applicant, In view of deletion of claims 6-10, the objection is now rendered moot.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
Discuss a research question related to BOEHRINGER INGELHEIM INTERNATIONAL GMBH Received a Patent
Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.
Discuss a research questionSource and context: Original GIPResearch.com publication dated 2019-10-09. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

How to patent fintech inventions
Gen AI Innovations
What is Extended Reality
How to patent artificial intelligence based innovations
Patent claim drafting